Answers are grounded in this paper and cite their sources.
The front cover picture shows the pan-cyclin-dependent kinase (CDK) inhibitor BAY 1000394 embedded in a schematic depiction of the cell cycle and a colored paraffin section of an untreated A2780Cis ovarian cancer tumor grown on a nude mouse. Aminopyrimdine BAY 1000394 is a balanced, orally available pan-CDK inhibitor with potent, broad-spectrum antiproliferative activity against human cancer cell lines, and is currently being investigated in a phase I clinical trial in patients with advanced solid tumors. For more details, see the Full Paper by Ulrich Lücking et al. on p. 1067 ff.
No takes yet. Share an insight, caveat, or question.
Lücking et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: